Abstract | Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. It results from an accumulation of genetic and epigenetic changes in colon epithelial cells, which transforms them into adenocarcinomas. Over the past decade, major advances have been made in understanding cancer epigenetics, particularly regarding aberrant DNA methylation. Assessment of the colon cancer epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has hundreds to thousands of abnormally methylated genes. As with gene mutations in the cancer genome, a subset of these methylated genes, called driver genes, is presumed to have a functional role in CRC. The assessment of methylated genes in CRCs has also revealed a unique molecular subgroup of CRCs called CpG island methylator phenotype (CIMP) cancers; these tumors have a particularly high frequency of methylated genes. These advances in our understanding of aberrant methylation in CRC have led to epigenetic alterations being developed as clinical biomarkers for diagnostic, prognostic and therapeutic applications. Progress in this field suggests that these epigenetic alterations will be commonly used in the near future to direct the prevention and treatment of CRC.
Introduction
Colorectal cancer (CRC) results from the accumula tion of both acquired genetic and epigenetic changes that transform normal glandular epithelium into inva sive adenocarcinoma. The steps involved in this process were first described in the classic adenoma→cancer pro gression model proposed by Fearon and Vogelstein in 1990 . 1 Since this model was originally proposed, our understanding of the molecular pathogenesis of CRC has advanced consider ably, resulting in numerous revi sions of the initial model. The original model was based on the premise that tubular and tubulovillous adenomas were the premalignant neoplasms that would progress to invasive adenocarcinoma. However, it is now recog nized that additional classes of premalignant polyps, such as serrated polyps, also have significant potential for malignant transformation. 2 Furthermore, the origi nal model proposed a fairly limited repertoire of genetic alterations that drove the formation of CRC. It is now appreciated that there are multiple molecular pathways to CRC, and that these pathways involve both mutations and epigenetic alterations. For example, serrated polyps are associated with microsatellite instability and aber rant DNA methylation, whereas tubular adenomas more commonly arise via inactivation of the APC tumor sup pressor gene and concurrent genetic alterations resulting from chromosomal instability. 3 At the present time, it is understood that there are at least three, and probably more, polyp→cancer progression sequences that arise via different mol ecular events. 4 These changes to the origi nal model highlight that not only are there histological differences in CRCs but that important molecular differences also exist amongst these cancers.
That thousands of molecular alterations can be found in the average CRC genome is now understood, and it is widely believed that only a subset of these alterations drive the cellular and clinical behavior of the cancer. These key molecular features of tumors will ultimately be useful for understanding the environmental and genetic factors that lead to CRC, for predicting the natural history of the tumors, and for determining a specific cancer's likelihood of responding to therapy. In fact, the molecular heterogeneity of CRC is believed to be one of the factors responsible for the considerable variability in treatment response among patients with the same stage of CRC; 5 although defined molecular subtypes of CRC exist, the molecular subgroups cannot be accurately dis tinguished histologically or clinically at this time. The development of methods that can detect the major epi genetic and genetic changes in cancers should permit the identification of these molecular alterations, which can then be used as predictive markers. Efforts to character ize the molecular features of CRCs have already led to the development of clinical assays that detect KRAS muta tions; these assays can be used to direct therapy with anti EGFR (epidermal growth factor receptor) monoclonal antibodies in patients with metastatic CRC. advanced than that of our understanding of gene muta tions, but substantial progress has been made in this area. This Review provides an overview of the role of epi genetics in CRC, including the contribution of epi genetics to the molecular heterogeneity of CRC. We also discuss the clinical applications of these epigenetic alterations as biomarkers for early detection, diagnosis, prognostication and management of patients with CRC.
The molecular pathogenesis of CRC
The classic view of cancer is that it arises as a conse quence of the accumulation of mutations in key tumor suppressor genes or oncogenes, which deregulate homeostatic functions and cause the transformation of normal cells into cancer cells. Sequencing of colon cancer genomes has revealed that there are only a small number of functionally important gene mutations out of the hun dreds of mutations found in the average colon cancer genome; an analysis of approximately 13,000 genes revealed mutations in the coding sequence of approxi mately 67 genes in the average colon cancer genome, of which a subset of 12 genes were proposed to be the genes most likely to be involved with cancer formation in individual cancers. 8 The current cancer genome sequenc ing efforts demonstrate that most cancer genomes carry hundreds of mutations, providing a major challenge to determine which of these mutations have a pathogenic role in the formation of the cancer ('driver mutations') and which are merely a consequence of this process ('pas senger mutations'). Furthermore, CRCs can be divided into groups depending on the type of genomic instability that they display. They can be grouped into those with chromosomal instability (CIN), which is characterized by aneuploidy and chromosomal gains and losses, and those with micro satellite instability (MSI), which is identi fied by the presence of frequent insertion and dele tion mutations in repetitive DNA sequences. 9 ,10 Different patterns of mutant genes can be seen in the MSI versus the CIN tumors, which suggests that the underlying form of genomic instability in the cancer influences the suscepti bility to and selection for specific mutations.
The role of gene mutations in cancer formation can be appreciated in even the earliest lesions involved in the polyp→cancer progression sequence. The first identifi able histological lesion implicated in CRC formation is the aberrant crypt focus. Dysplastic aberrant crypt foci can harbor mutations in APC, one of the most frequently mutated tumor suppressor genes in CRC. Inactivation of APC leads to activation of the Wingless/Wnt pathway, a common mechanism for initiating the polyp→cancer progression sequence. 11 Subsequent to mutations in APC or other genes of the Wnt signaling pathway, mutations in genes such as KRAS or TP53 occur and foster the clonal progression of the polyp cells to cancer. 11, 12 Progression can involve KRAS and TP53 mutations as well as muta tions in genes that regulate important cell signaling pathways such as the transforming growth factor β (TGFB1) signaling pathway. 13 Mutations in the type II TGFβ receptor (TGFBR2) gene occur in approximately 30% of CRCs. 14 The type of mutation that inactivates TGFBR2 depends upon the molecular subtype of the developing cancer cell. 14, 15 In addition, mutations and epigenetic alterations affecting other TGFB1 signaling pathway members, including SMAD2, SMAD4, RUNX3 and TSP1, have been identified in colon cancers. 8, 13, [16] [17] [18] Ultimately, it is believed that although the underlying form of genomic or epigenomic instability determines the types of mutations that occur in colon cancer, the selective pressures that lead to the clonal evolution of the tumors are largely the same across all CRCs. This concept explains why certain genes are more frequently mutated in colon cancers than in other cancer types (for example, breast cancer or prostate cancer) and vice versa.
Gene mutations and epigenetic alterations have been proposed to contribute to colon cancer formation through the activation of oncogenes and the inactiva tion of tumor suppressor genes that regulate signaling pathways that control hallmark behaviors of cancers. 19 For example, KRAS is a protooncogene that is a down stream effector of EGFR. It signals through BRAF to acti vate the MAPK pathway. Mutations in KRAS or BRAF occur in approximately 55-60% of CRCs, aberrantly activating the MAPK signaling pathway, thus inducing proliferation and suppressing apoptosis. 20, 21 The most common signaling pathways that carry mutant genes in CRC include not only the RAS-RAF-MAPK pathway, but also the PI3K pathway, the WNT-APC-CTNNB1 pathway and the TGFB1-SMAD pathway. 22 Insights into the biology of CRCs have resulted from the identification of genes commonly mutated in these particular pathways in colon cancer and have led to paradigms that have informed the study of epigenetic alterations in cancer. These insights are also currently being used to develop new diagnostic and prognostic assays for CRC, as well as new therapies.
Epigenetic alterations and cancer
The study of gene mutations in CRC has established our current understanding of the role of molecular altera tions in the development of colon cancer, and has led to the intense investigation of epigenetic alterations in cancer. Epigenetics broadly refers to heritable alterations in gene expression that are not mediated by changes in the DNA sequence. The epigenetic regulation of gene expression occurs in normal tissue and has an important role in embryonic development, imprinting and tissue differentiation. 23 In 1982, aberrant epigenetic alterations were first discovered in CRC. Since that time, research has revealed an 'epigenetic landscape' consisting of a complex array of epigenetic regulatory mechanisms that control gene expression in both normal tissue and cancerous tissue. 24, 25 The epigenetic landscape is largely a reflection of factors that determine the condensation state of chromatin, which determines whether the DNA is accessible to proteins that control gene transcription. A relaxed or 'open' chromatin state allows for gene trans cription, whereas a condensed or 'closed' chromatin state prevents gene transcription. 23 The epigenetic mechanisms currently believed to have a role in cancer development include: DNA methylation of cytosine bases in CGrich sequences, called CpG islands; posttranslational modification of histones (proteins that form the nucleosomes), which regulate the packaging structure of DNA (called chromatin); microRNAs and noncoding RNAs; and nucleosome positioning. 23 In this Review, we focus on aberrant DNA methylation as it is the most extensively studied deregulated epigenetic mecha nism in CRC. A number of excellent reviews on other classes of epigenetic alterations, such as histone modifica tions, have been written, and the interested reader is directed to those reviews for further information.
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Overview of DNA methylation DNA methylation refers to the enzymatic addition of a methyl group to the 5'position of cytosine by DNA methyltransferases (DNMTs) to produce 5methyl cytosine, a normal base in DNA. 30 Generally, the favored substrate for DNMTs is a CG dinucleotide sequence (called CpGs). In normal mammalian cells, the majority of CpGs are methylated, with unmethylated CpGs being typically present only in regions of DNA called CpG islands. CpG islands are regions in the genome where the percentage of the CpG dinucleotides is higher than would be expected, based upon a random distribution of nucleotides. Of interest, CpGs are generally under represented in the genome presumably due to the sus ceptibility of 5methylcytosines to undergo transition mutations secondary to deamination. 31 CpG islands are often defined as sequences >200-500 bases in length with greater than 50% CG content and a ratio of observed to expected CpGs of >0.6. 32 CpG islands overlap the pro moter region of 60-70% of genes and tend to be protected from methylation; however, they can become aberrantly methylated in cancer owing to the disruption in barrier elements that normally protect these CpG islands from methylation. 33, 34 Methylation of CpG islands within the promoter region is correlated with transcriptional silenc ing, although it seems that decreased gene expression is only characteristic of a subset of methylated genes in CRC (Figure 1) . 35, 36 Methylation that occurs in CpG sites outside of promoter regions, termed genebody methyla tion, does not correlate with transcriptional inactivation. In fact, paradoxically, genebody methylation has been correlated with transcriptional activation. 37 It is important to recognize that DNA methylation is a normal mechanism in the mammalian genome by which cells regulate gene expression, and that the major ity of the CpG sites in the human genome are located outside of promoter regions and are heavily methylated. For example, DNA methylation is a major mechanism for X chromosome inactivation and genomic imprint ing. 38 As mentioned previously, the methylation state of a gene is regulated by DNMTs, including DNMT1, DNMT3a and DNMT3b, which transfer methyl groups from Sadenosylmethionine to DNA in either a de novo (DNMT3a and DNMT3b), or maintenance fashion (DNMT1). De novo methylation refers to the methyla tion of DNA without the use of a DNA template that carries an existing methylation pattern; maintenance methylation occurs during DNA replication, and refers to the replication of the methylation pattern of the unrepli cated strand of DNA onto the newly replicated strand of DNA. 30, 39, 40 Other important roles for DNA methylation include silencing of repetitive centromeric sequences as well as transposons and other endoparasitic sequences; these latter functions seem to be important for maintaining genomic stability ( Figure 1 ). [41] [42] [43] Gene methylation patterns are established during development by the de novo DNMTs and are critical for gene regulation. Methylation of CpGs can lead to trans criptional inactivation via multiple mechanisms, including directly inhibiting cisbinding elements, such as the transcription factors AP2, CREB, E2F, CBF and nuclear factor κB (NFκB). [44] [45] [46] [47] [48] A prominent mechanism by which DNA methylation is thought to regulate gene expression is through cooperative interactions with enzymes that regulate the chromatin structure, which can induce a compacted chromatin environment that represses gene expression. 36 A family of proteins called methylbinding proteins are involved in these coopera tive interactions by binding with high affinity to meth ylated DNA. This step leads to a cascade of events that can alter chromatin structure by recruiting proteins that regulate histone acetylation, histone methylation and chromatin remodeling, thereby condensing the chro matin and blocking access of transcription factors to the promoter region. 36 These proteins include the follow ing: methyl domain binding proteins, MeCP2, MBD1, MBD2 and MBD4; the zinc finger proteins Kaiso, ZBTB4 and ZBTB38; and the SETand RINGfinger associated proteins, UHRF1 and UHRF2 among others. 29, 49 The interaction between DNA methylation, histone modification and chromatin structure is complex, with abundant crosstalk. DNA methylation can affect chro matin structure, as outlined above, but the converse is also true. For example, dysregulation of histones and their modifying proteins might cause aberrant DNA methylation. Polycomb group proteins (PcG) have been implicated in the predisposition of promoters to both normal methylation and cancerrelated methylation. 49 PcG protein complexes PRC1 and PRC2 regulate gene expression during embryonic development through their effects on posttranslational histone modification states and chromatin condensation. Polycombmediated repression involves proteins commonly overexpressed in cancer, such as EZH2, and cooperates with aberrant DNA methylation to silence gene expression by regulat ing chromatin compaction. 49 A close association exists between methylated CpG islands and histones contain ing repressive posttranslational modifications (such as H3K9me3 and H3K27me3). The establishment of these histone modifications (which cause chromatin condensa tion) is thought to be mediated by polycomb repressive complexes. 50, 51 This association has raised the possibility that abnormal activity of PRC2 might be the mechanism for inducing aberrant DNA methylation in cancer. 31 Feinberg and colleagues have extended the concept of CpG islands to 'CpG island shores' , which are also abnormally methylated in cancer. CpG island shores refer to areas of less dense CpG dinucleotides within 2 kb upstream of a CpG island. 52 The methylation of CpG island shores is also associated with trans criptional inactiva tion and expression of splice variants. The methyla tion of these CpG island shores tends to be tissue specific, and has been shown to be altered in CRC. 52, 53 This driving role of aberrant methylation of CpG island shores in the development of cancer is still controversial and remains to be proven with additional studies but, if true, it could potentially explain certain phenomenon related to cancer epi genetics that are poorly under stood at this time, such as cancerrelated alterations in RNA splicing.
DNA methylation and cancer
Although the importance of gene mutations in the pathogenesis of cancer is widely accepted, the role of epi genetic alterations in cancer has been controversial until the past decade. The first epigenetic alteration in cancer was reported nearly three decades ago by Feinberg and Vogelstein, who showed extensive global loss of 5methyl cytosine content in colon cancers com pared with the normal colon. 54 The global loss of DNA methylation predominantly affects CpG dinucleotides found in repetitive sequences of DNA, such as LINE1 and satellite repeats. This global hypomethylation can be found in the colon in an agedependent fashion as well as in the early steps of the polyp→cancer progres sion sequence. [55] [56] [57] Thus, it seems that the global hypo methylation of DNA is an early event in the formation of CRC. A study in Dnmt1 +/-mice demonstrated that DNA hypomethylation might contribute to cancer formation by permitting or inducing genomic instability. 42 It might also lead to loss of imprinting (LOI), which can result in the overexpression of imprinted genes such as IGF2 and predispose an individual to cancer. 58, 59 After the discovery of DNA hypomethylation in cancer, the DNA methylation pattern of normally unmethylated CpG islands in gene promoters of many types of neoplasms was shown to be aberrantly hyper methylated, which is yet another distortion of normal methylation patterns. 55 Genomewide studies of cancer epigenomes have revealed that 1-10% of CpG islands are , whereas methylated CpG islands are correlated with a condensed, closed chromatin structure (heterochromatin) and transcriptional silencing. Normal colonic epithelium generally has unmethylated CpG islands in the promoter regions of genes, whereas aberrant hypermethylation of promoter associated CpG islands is a hallmark of neoplasms. In addition to the aberrant local hypermethylation seen in colorectal cancers, global hypomethylation at LINE-1 sequences is also observed, which has been shown to be associated with genomic instability. Interestingly, an inverse association exists between local CpG island hypermethylation and global LINE-1 hypomethylation as colonic neoplasms progress.
aberrantly methylated, which suggests that thousands of gene promoters might be hypermethylated in the average cancer. 60, 61 The identification of hypermethylation of classic tumor suppressor genes, including CDKN2A, MLH1, CDH1 and VHL, provided indirect support for the functional role of aberrant DNA methylation in the cancer formation process. [62] [63] [64] [65] However, the importance of global hypomethylation and aberrant CpG island hypermethylation was not immediately evident, leaving open the idea that the epigenetic alterations in cancers, including CRCs, are merely bystander phenomena in the cancer genome.
The idea of epigenetic alterations being only pas senger events in cancer has since been disproven over the past decade by innovative studies that have led to a richer understanding of the driver role of epigenetic alterations in the development of cancer. [66] [67] [68] It is now accepted that both epigenetic alterations, as well as gene mutations, cooperate to drive the progression of normal cells to cancer cells. The aberrant hypermethylation of genes seems to be a common molecular mechanism for silencing tumor suppressor genes and can contribute to cancer formation through the transcriptional repression of these genes. In fact, it seems that in the average colon cancer genome, many more genes are affected by aber rant methylation than by mutations, and that aberrant methylation is the only mechanism observed for the silencing of many genes in cancer. 49, 69 Thus, although Knudson's 'twohit hypothesis' initially referred to gene mutations (either germline or somatic), 70 it is now under stood that the 'second hit' can be an epigenetic altera tion. Both genetic and epigenetic events are comparable in the selective advantage that the event can confer to a cell's ability to become a cancer cell. Interestingly, the specific genes that are commonly found to be methylated in colon cancer often differ from those commonly found to be methylated in other tumor types, which indicates a selective process that drives the occurrence of methylated genes in different tumor types.
Mechanisms of aberrant DNA methylation
The processes that mediate aberrant DNA hypermethyla tion and hypomethylation are currently under investiga tion. Although specific mechanisms have yet to be identified, it is now clear that DNA methylation is regu lated through reciprocal interactions with histones, and that alterations in the posttranslational state of histones are closely associated with cancerrelated alterations in DNA methylation. 31 Whether the aberrant methylation of genes in colon cancer results primarily from 'selec tive targeting' (which reflects a predisposition of certain genes to become hypermethylated) or 'selective advan tage' (which reflects the clonal outgrowth of cells that have methylated specific genes) or a combination of the two forces is not currently known. 31 
Selective targeting
With regards to mechanisms that could be involved with selective targeting, the two major competing models to explain the aberrant methylation of DNA observed in cancer are either: the enzymes that mediate DNA methyla tion, DNMT1, DNTM3a, and DNMT3b, are overexpressed, hyperactive or misdirected; or the 'barrier elements' that normally prevent DNA methylation of specific regions of DNA are impaired.
Increased DNMT expression has been proposed as a mechanism for the increased methylation that occurs in the promoter region of tumors. Both increased expression and increased activity of the DNMTs have been reported in human cancers, including colon cancer, compared with normal tissues. [71] [72] [73] [74] Both animal and cell line models have consistently demonstrated that overexpression of DNMT1 and DNMT3b can induce aberrant methyla tion of normally unmethylated CpG islands, similar to what is seen in human colon cancer. 31, 72, 73, 75 However, the results of studies in primary cancers are mixed, with some studies showing increased DNMT1 expression and others showing no evidence of increased expression, particularly after normalizing for cancer cell prolifera tion. 76 In fact, it might be that the fundamental defect is not increased activity of the DNMTs, but rather mis directed activity. DNMT activity can be directed to spe cific loci, at least in part, by histone methyltransferases and histone demethylases, such as EHMT2, PRMT5 and SUV39H1, which might mediate some aspects of aber rant DNA methylation in certain cancers. Furthermore, polycomb mediated premarks, indicated by histone H3K27 methyla tion, have been shown to recruit DNMTs, and could, therefore, have a role in the misdirection of methyl transferases in cancer. 77, 78 Evidence also exists that cisacting DNA sequences are susceptible to cancer specific DNA methyla tion. In vitro studies have shown 500fold differ ences in the methylation rate of preferred sequences (for example, CTTGCGCAAG) compared with resistant sequences (for example, TGTTCGGTGG). 23, 79, 80 The deregulation of DNMT activity in cancer can also be shown by assessing the methylation entropy status of the cancer genome, which reveals that cancer cells have decreased DNMT fidelity at Alu repetitive sequences and promoter associated CpG islands. This finding sug gests that the inherent defect in cancer cells is related to decreased enzyme fidelity and not hyperactivity. 81 Another major mechanism that might be involved in aberrant methylation of specific loci is the impair ment of barrier elements in cancer cells compared with in normal cells. Barrier elements are postulated to be established by specific DNA sequence elements and their associated binding proteins, and are thought to protect genes from inappropriate signals from the surround ing genomic landscape, including DNA methylation. Proposed barrier elements include: steric occupancy of DNA regions by proteins such as PolII; DNA binding by histones with specific modification states; SP1 binding sites; and VEZF1 elements. 49, 82 A 'DNA neighborhood effect' has been proposed as a mechanism for aberrant hyper methylation seen in tumors as a result of impaired barrier function. The DNA neighborhood effect is the concept of methylation spreading from densely methyl ated areas to surrounding sequences. In support of this idea, it has been shown that epigenetic silencing by DNA methylation can occur across a band of chromosome up to 1 Mb in size. 83 However, there are also many examples of locusspecific aberrant DNA methylation with no obvious neighborhood effect on adjacent loci. 49 
Selective advantage
In addition to selective targeting, there is also evidence for an element of 'selective advantage' driving the aber rant methylation of genes in cancer. Although it is unlikely that aberrant DNA methylation is strictly a random event and that the methylated genes observed in colon cancer merely reflect clonal growth advantage resulting from the abnormal methylation, it is likely that many of the methylated genes observed in colon cancer are present in the tumors because their methyla tion created a clonal growth advantage. Consistent with the concept of selective advantage, cancers have tumor typespecific methyla tion patterns and the frequency of specific methylated genes varies widely between tumor types. 43 Other mechanisms Other models have also been proposed to explain the aberrant DNA methylation observed in cancers. One model is that the epigenetic alterations observed in colon cancers are reflective of the stem cells from which the colon epithelial cells are derived, and that the alterations observed in the cancers merely indicate the undiffer entiated state of the tumor cells. 23 It has also been proposed that unrepaired inflammationmediated halogenated DNA damage products can mimic 5methyl cytosine due to their high affinity for methylbinding proteins and ability to induce methylation of the daugh ter strand after DNA replication, leading to the establish ment and propagation of aberrant methylation. [84] [85] [86] This proposed mechanism supports the idea that misdirected, rather than hyperactive, DNMT activity leads to aberrant DNA methylation.
Dysregulation of noncoding RNAs, including micro RNAs (miRNAs) and piwiinteracting RNAs (piRNAs), also contributes to epigenetic deregulation in plants and might have a similar role in the human genome. Emerging data show that, in humans, miRNAs can induce aberrant DNA methylation by directly target ing DNA methyltransferases. [87] [88] [89] To date there is only one example of a noncodingRNAmediated regulatory mechanism in mammalian genomes, and this involves piRNAs. 90 Neither of these mechanisms-aberrant DNA methylation secondary to loss of miRNA medi ated suppression of DNA methyltransferases, or the aberrant localization of DNMTs to specific loci by non coding RNAs and miRNAs-seem to be a generalized mechanism for regulating DNA methylation. However, conversely, it does seem that aberrant DNA methylation can silence miRNA expression in cancers-an important role in the pathogenesis of CRCs. 91 In addition to mis direction of DNA methylation and miRNA dysregula tion, it is also possible that environmental agents might act as epimutagens and contribute to aberrant DNA methylation in some tumors. 43 Thus, there are many proposed mechanisms by which epigenetic gene regulation is thought to be dysregulated in cancer, and each mechanism is supported by evi dence from a variety of different lines of experimental approaches. It is likely that no single mechanism is suffi cient to alter the cellular process and drive the patho genesis of aberrant DNA methylation in cancer. Rather, probably all of these mechanisms contribute to the aberrant epigenetic regulation seen in human cancers, depending on the circumstances of the tumor.
Aberrant DNA methylation in CRC DNA methylation and age Age is an important risk factor in the development of CRC, and aging colonic mucosa shows agerelated global hypomethylation as well as locusspecific DNA hypermethylation. 92 Initially, the aberrant methyla tion of ESR1, IGF2 and TUSC3 was shown to occur in histologically normal colon epithelium in an age dependent fashion, and subsequently other genes were also shown to exhibit agedependent methylation. [93] [94] [95] Approximately half of the genes that show agerelated methylation are the same genes as those involved in the pathogenesis of colon cancer, which suggests a role for these genes in the increased cancer susceptibility that is associated with aging. Interestingly, not only is aberrant hypermethylation of specific gene pro moters seen in aging, but evidence exists that global loss of methyla tion occurs during the aging process, which suggests that the mechanism(s) responsible for agerelated and cancerrelated DNA methylation might be shared. [96] [97] [98] However, the cause of agerelated aberrant methylation is not known. There is evidence to suggest that agerelated hyper methylation occurs after the development of local predisposing factors in DNA that affect transcription factor binding sites and repetitive sites such as SP1 binding sites and tandem B1 elements, respectively, as a result of environmental exposures, or secondary to a genetic predisposition to DNA methylation. 98 SP1 binding sites and tandem B1 elements have been proposed to regulate DNA methyla tion through different mechanisms. SP1 transcription factors regulate the expression of a variety of genes, in part through recruiting chromatinmodifying enzymes to the promoters. Impaired SP1 DNA binding might be an agerelated phenomenon that leads to increased DNA methyla tion through indirectly changing chroma tin structure. By contrast, tandem B1 elements are DNA sequences that have been shown to serve as methylation centers in mice. 99 Tandem B1 elements could be hyper active in aging tissues. It has been shown that single nucleotide polymorphism (SNP) variants in MTHFR exist and have a role in regulating the availability of the methyl donor for DNMT1. 100, 101 Transcriptional control of DNMTs is altered in aged cell lines, and it is possible that the global decrease in methylation seen in aging is a result of a progressive decrease in DNMT1 mainte nance activity on heterochromatin, whereas upregula tion of the de novo methyltransferase DNMT3b could be responsible for the hypermethylation seen in aging. 71, 98, 102 The implica tion of the aberrant DNA methylation observed in the normal tissues of older individuals is that colon cancers arising in older people might have more epigenetic driver events than those seen in younger people. 103 
DNA methylation and field cancerization
In 1953, Slaughter et al. introduced the concept of field cancerization in the context of oral squamous cell carcinoma to explain the development of multiple primary tumors, local recurrence, abnormal tissue surrounding the cancer and multifocal areas of pre cancerous change. 104 The concept of field canceriza tion reflects the susceptibility of the normal tissue to develop cancer, possibly as a result of an environ mental exposure. This concept was conceived on the basis of histological observa tions; however, today it is clear that field canceriza tion occurs at the molecular level. Preneoplastic cells with clonal relation ship to the tumor can persist after complete resection of the tumor, and it is not clear how far the cancer field can extend from the primary tumor; it might even involve the entire organ. 105 There is evidence consistent with the concept of field cancerization for numerous types of cancers, including CRC. 106 Some studies have established that epigenetic alterations could be indicators of field cancerization in the colon. 107, 108 In support of the role of methylated genes as effec tors of the earliest steps in cancer formation, studies of primary human mammary epithelial cells have shown that the aberrant methylation of genes is associated with immortalization as well as with subsequent steps in the malignant progression of these cells. 109 It has also been proposed that the aberrant methylation of genes might lock stem cells in an undifferentiated state, pre disposing them to malignant transformation. 110 Shen et al. showed that 50% of tumoradjacent histologically normal tissue carried detectable methylated MGMT (O6methylguanine methyltransferase) when the primary tumor had methylated MGMT, whereas only 12% of histologically normal tissue from cancerfree control patients had MGMT promoter methylation. In cases in which the primary tumor did not have methy lated MGMT, only 6% of the tumoradjacent normal tissue carried methylated MGMT. 111 A field canceriza tion effect-as assessed by hypomethylated CDH3 (the gene for Pcadherin), methylated EVL, and methylated p14-in normal colon epithelium adjacent to colon cancer has also been shown. [112] [113] [114] In an extension of singlegene studies, Belshaw et al. assessed agedependent gene methylation of a panel of genes (including APC, AXIN2, DKK1, HPP1, TUSC3, p16, SFRP1, SFRP2 and SFRP4) in normal colon mucosa and found marked differences in gene methylation levels between people with and without colon neoplasms. They employed a multinomial logistic regression model based on the DNA methylation status of APC, TMEFF2 (HPP1), CDKN2A (p16), SFRP4, WIF1 and ESR1 of the normal mucosa of patients with cancer as well as of normal patients, and were able to correctly identify 79% of patients with cancer and 88% of cancerfree patients. 115 Other groups have similarly found panels of methylated genes in the normal colon mucosa that corre late with concurrent neoplasm status, although different genes have been used in the different studies. 108 Further evidence for the role of methylation field defects as effectors in cancerization comes from studies of synchronous tumors. Synchronous CRCs have been shown to have similar epigenetic events through con cordant DNA methylation patterns in multiple genes thought to be important in colorectal carcinogenesis. 74, 116 A major question related to field cancerization is what underlying factor mediates this process. Although some studies have shown a correlation with folate exposure, most studies have not identified an association with folate exposure and the methylation state of genes in the normal colonic mucosa. 117 Of interest, the methylation state of DNA repair genes, such as MGMT and MLH1, in the adjacent normal mucosa can also be shown to correlate with specific mutations in the tumor DNA, such as KRAS mutations or microsatellite instability, respectively, which are pre dicted to result from loss of function of these DNA repair genes. 107, 118 This finding suggests that epigenetic altera tions create a predisposition for specific cancerrelated mutations. 107, 118 Furthermore, hypermethylation and downregulation of SFRP genes are present in mono clonal aberrant crypt foci lacking APC mutations. This step is thought to contribute to constitutive WNT ligand signaling and decreased apoptosis, which may cancer ize the field and make those cells particularly sensitive to further activating events in the WNT pathway. 68 The methylation patterns of SFRP genes, which regulate the WNT signaling pathway, could be useful for predict ing the risk of developing colon cancer. 115 However, the relationship between aberrant gene methylation in the normal colonic mucosa and priming of the mucosa to undergo cancer formation seems to be complex, as there are also data suggesting that the hypomethylation of genes that undergo agerelated DNA methylation cor relates with the presence of colorectal neoplasms in the CIMP molecular class. 108 At this time, it still remains to be determined whether the methylated genes detected in the normal mucosa are truly indicative of a field effect in the colon or are a marker of an associated phenom enon, such as folate status or tobacco exposure. 119, 120 It is also clear that the methylation state of the right and left colon varies, and that this aspect of normal mucosa sampling needs to be taken into consideration when measuring the methylation state of genes in normal colonic mucosa. 121, 122 DNA methylation in the pathogenesis of CRC Hundreds to thousands of genes are thought to be aber rantly methylated in the average CRC genome, and only a subset of these genes is likely to be important in the pathogenesis of these cancers. Of these methyl ated genes, many have already been shown to be com monly hyper methylated as well as silenced in CRC (Table 1) . Our understanding of the role that aberrantly REVIEWS methylated genes have in the initiation and progression of the polyp→cancer sequence continues to evolve as additional methylated genes are identified ( Figure 2 ). As might be expected given the detection of methyl ated genes in the normal mucosa of people at increased risk of CRC, methylated genes can be detected in aberrant crypt foci and adenomas as well as in adeno carcinomas. 123 Examples of genes methylated early in the adenoma→carcinoma sequence include ITGA4, MGMT, SLC5A8, SFRP2 and MINT1. [123] [124] [125] [126] [127] [128] Notably, the most substantial increase in gene methylation is seen in the normal mucosa to adenoma step of the polyp→cancer progression sequence. 128 The proportion of neoplasms that carry methylated genes is not markedly different between advanced adenomas and adenocarcinomas, but the frequency of methylation of specific genes does vary between early adenomas, advanced adenomas and adenocarcinomas. 128, 129 LINE1 DNA hypomethylation in the polyp→cancer sequence shares a similar pattern with local promoter hypermethylation in that there is a substantial difference in the levels of LINE1 hypo methylation and local hypermethylation occurring at the polyp to adenoma step of the sequence, but no difference between levels at the adenoma to cancer step. 130 There is no clear functional class of genes that seem to be more commonly affected by DNA methylation in the adenoma step of colon cancer development compared with other steps in the progression sequence. 129 Despite the lack of definitive proof, it has been proposed that aberrant methylation of DNA repair genes, such as MGMT and MLH1, in colon adenomas might promote the progres sion of adenomas to cancer by creating a permissive state for G>A mutations-the most common mutation seen in KRAS in the case of methylated MGMT, and a per missive state for micro satellite instability in the case of methylated MLH1. 131, 132 In addition to the detection of methylated genes in adenomas, CIMP can be detected in advanced tubular adenomas but is not commonly observed in early tubular adenomas. 128, 133 Interestingly, Kwon et al. detected CIMP adenomas in a collection of serrated adenomas but not in tubular adenomas, which suggests that serrated adenomas could be the precursor polyps for CIMP CRCs. 133 It is not clear whether the detec tion of CIMP late in the polyp phase of CRC forma tion reflects a technical issue regarding the number of loci assessed in the studies of methylated genes in ade nomas, or demon strates that CIMP occurs late in the polyp→cancer sequence. 128 This is an issue because it is widely believed that CIMP tumors might arise from ser rated adenomas, in which case it would be reasonable to assume that CIMP would be detected in early adenomas. To date, methylated genes that distinguish sessile ser rated adenomas from hyperplastic polyps (CDX2, MLH1, and TLR2) have been identified, but there has yet to be consistent reporting of a subset of early adenomas with the CIMP signature of methylated genes. 134 
DNA methylation and metastatic CRC
The progression of colonic adenomas to adeno carcinomas is believed to be driven by genetic altera tions, such as mutations in TP53, but is also probably a consequence of epigenetic alterations (Figure 2 ). For example, the aberrant methylation of CXCL12, a chemo kine ligand, occurs in human CRC and can promote the metastatic behavior of colon cancer cell lines. 135 In addi tion, the frequency of tumors carrying certain methyl ated genes, like TIMP3, ID4 and IRF8, is higher in colon cancer and metastases than adenomas, suggesting that the inactivation of these genes by methylation provides a clonal growth advantage. 128, 136 In addition to specific aberrantly methylated genes being present in advanced CRCs, hypomethylated LINE1 elements are found to increase linearly in more progressed colon neoplasms (Figure 1) . 130, 137, 138 However, in general, it seems that the aberrant DNA methylation of genes is predominantly involved with the early events of colon cancer formation and less with progression events.
DNA methylation epigenotypes of CRC
Epigenetic instability in CRC is manifested in a variety of ways, including hypermethylation of gene promoters that contain CpG islands and global DNA hypomethylation. Essentially all CRCs have at least some aberrantly methyl ated genes, and there seems to be a unimodal distribu tion of colon cancers when the proportion of methylated genes to cancer genome is assessed. In 1999, Toyota and Issa observed that some CRCs have a high frequency of methylated genes, and they put forth the concept that these tumors have a unique molecular patho genesis, naming them CIMP cancers. 93 This concept was met with Figure 2 | Commonly methylated genes (and loci) identified at the histological steps of the colorectal cancer polyp adenocarcinoma sequence. Specific gene and loci hypermethylation has been observed in the different steps of the cancer progression sequence, which implicates these genes in either the initiation or progression of colorectal cancer. The genes listed between normal epithelium and aberrant crypt focus as well as those genes listed between aberrant crypt focus and polyp/adenoma might be involved in the initiation of colorectal cancer. Those genes listed between polyp/adenoma and adenocarcinoma could have a role in the progression and metastasis of colorectal cancer. Note that only the genes (and loci) that have consistently been found to be hypermethylated at specific points in the progression sequence have been included. *MINT1 and MINT31 are not genes; rather they are loci that have been found to be 'methylated in tumor' (aka MINT).
considerable controversy, but has since been adopted owing to the substantial accumulated supporting evi dence. Approximately 20% of CRCs are CIMP tumors, 139 and these tumors are currently identified by having >60% of methylated genes in a preselected panel of 'CIMP marker' genes. The panel of genes for defining CIMP still remains to be standardized, thus the criteria used to identify CIMP tumors can vary across studies, which makes generalizing results across studies difficult. 7, [140] [141] [142] A commonly used panel is one defined by Weisenberger et al., which includes NEUROG1, SOCS1, RUNX3, IGF2 and CACNA1G; however, it remains to be determined which panel will ultimately be selected for determining the CIMP status of CRCs. 143 Regardless of which panel of CIMP markers is used, CIMP tumors have a high fre quency of BRAF c.1799T>A(p.V600E) mutations, tend to occur in the right colon and are more common in women than men. 143, 144 The underlying cause of CIMP tumors is not known at this time, but an association with cigarette smoking has been demonstrated. 120, 145 Associations with nutritional status, body size and physical activity have also been shown; severe energy restriction during childhood is associated with a reduced risk of CIMP tumors, whereas increased BMI is associated with an increased risk of both CIMP and nonCIMP cancers. 146, 147 Although expected, no correlation between CIMP tumor status and folate status or alcohol consumption, which would contribute to folate deficiency, has been observed. 101, 148 Lastly, it seems that CIMP tumors arise most often from hyperplastic polyps or sessile serrated polyps, which sug gests that they are fundamentally different from CRCs arising from tubular adenomas. 149 In an extension of the CIMP concept, studies of the epigenomes of CRCs have identified groups of CRCs that segregate by epigenotype. 35, 142, 150 These epigeno types have unique associations with a variety of muta tions (for example, TP53, BRAF and KRAS) and with the genomic instability status of the cancer (for example, MSI, CIN or neither). 140, 151 The epigenotypes that have been proposed include different classes of CIMP, includ ing CIMPlow and CIMPhigh, which is determined by the proportion of methylated marker loci detected. 152 Shen and colleagues have suggested that CIMP colon cancers can be divided into two distinct classes, CIMP1 and CIMP2, on the basis of results of an unsupervised cluster analysis of a large panel of methylation markers. 151 A study of 97 primary CRC cases has shown that CIMP1 tumors are often microsatellite unstable (80%) and have BRAF mutations (53%), whereas CIMP2 tumors have KRAS mutations (92%), but rarely have MIS or BRAF or TP53 mutations. 151 Tumors that do not have CIMP have a high frequency of TP53 mutations (71%) and an inter mediate frequency of KRAS mutations (33%). 151 Finally, Hinoue et al. performed genomescale DNA methyla tion profiling of 125 CRCs and identified four DNA methylation based subgroups of CRC using modelbased cluster analyses. They classified the tumors as CIMP high, CIMPlow and nonCIMP. CIMPhigh exhibits an exceptionally high frequency of cancerspecific DNA hypermethylation, a strong association with methylated MLH1 and mutant BRAF c.1799T>A(p.V600E). CIMP low is associated with mutant KRAS 35, [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] and has a subset of CIMPhighassociated methylated genes rather than a unique group of CpG islands. Lastly, nonCIMP tumors are separated into two distinct clusters based on the association with mutant TP53 and location of the tumor. 35, 153 Although CIMP tumors and the distinct epigenotypes of CRCs described above do seem to represent distinct subsets of CRCs, the clinical utility of these designations is hindered by both the lack of a universally accepted definition of the CIMP phenotype and the lack of valida tion of the accuracy of the methylated gene panels for designating the epigentoypes. Finally, considerable overlap between CIMP and sporadic MSI tumors adds to the challenge of incorporating CIMPstatus into clini cal trials and clinical decisionmaking. 140 Retrospective study findings indicate that CIMP will ultimately be shown to be a predictive marker for CRC; however, cur rently, the data is not robust enough to recommend its clinical use. 151, 156 Thus, the discovery and classification of CIMP tumors has advanced our understanding of the molecular pathology of CRC, but has not yet influenced the clinical care of patients with this disease.
Mechanisms that give rise to CIMP are not yet clear, although a strong association exists between BRAFc.1799T>A(p.V600E) mutations and CIMP CRC, which suggests a role for activated BRAF in the patho genesis of the methylator phenotype and a link between sporadic MSI and CIMP. 140, 152 Structural equation model ing by Tanaka et al. has shown that the correlation struc ture of CpG island methylation can differ depending upon KRAS and BRAF mutation status, which suggests that distinct perturbations result in CIMP. 157 However, in vitro studies of mutant BRAF in CRC cell lines have not demonstrated a direct cause and effect relationship between BRAF and CIMP. 158 In prostate cancer, hyper methylation of the GSTP1 gene is a marker for disease and malignant transformation and might have a role in conjunction with elevated KLK (also known as prostatespecific antigen; PSA) for diagnosis and prognosis. 159 Hypermethylation of MGMT, which is a DNA repair enzyme involved in direct repair of alkyla tion damage products, was found to be predictive of a favorable response in gliomas to chemo therapy with alkylating agents, carmustine and temozolomide, and is the basis for the PredictMDX ® assay. Silencing of MGMT secondary to DNA methyla tion inactivates this DNA REVIEWS repair enzyme, which leads to an increased susceptibil ity of the gliomas to chemotherapyinduced alkylation DNA damage; consequently, methylated MGMT has been associated with improved outcomes from therapy with alkylating agents. 131 With regards to the use of methylated genes as bio markers specifically for CRC, the most advanced uses are as DNAbased CRC screening assays. Currently, colono scopy is still the most accurate test for CRC screening; however, it is costly and is associated with procedure related complications as well as poor patient compliance. By contrast, another commonly used CRC screening test, fecal occult blood testing (FOBT) is inexpensive and simple to perform, but has a relatively low sensitiv ity and specificity for the detection of colon adenomas. 160 Advances in our understanding of the mol ecular pathol ogy of CRC have led to the identification of promising early detection molecular markers for use in non invasive CRC screening assays. 161 Hypermethylation of promoter regions in CRC occurs early in some genes, and these methylated genes are being used as the basis for early detection markers (Table 2) . At this time, stoolbased methylated vimentin (mVim) is a clinically validated marker for early detection of CRC that is now commer cially available in the USA under the name ColoGuard ® . 162 The test exploits the fact that the vimentin gene (VIM) is aberrantly methylated in the majority of CRCs (53-84%) . 163 This early detection test is a PCRbased assay that simultaneously measures methylated VIM as well as DNA integrity and has a reported sensitivity of 83% and specificity of 82%, with approximately equal sensi tivity in patients with stage I-III CRC. 164 In addition, in Europe and the Middle East, a bloodbased assay that detects methylated SEPT9 is being marketed as a CRC screening assay under the name Epi pro Colon ® . Currently, methods are under development to enhance the performance of stoolbased and plasmabased methyla tion assays for clin ical purposes. 165 The use of molecular assays, such as the fecalmethylated VIM assay, in the clinical care of patients is likely to undergo rapid advances and be adopted into clinical practice over the next decade.
Clinical applications of methylated genes
Methylated genes might also be useful prognostic or predictive molecular markers for sporadic colon cancers.
As noted above, a number of genes are aberrantly methyl ated in colon cancer, including CDKN2A/p16, MGMT, THBS1, TIMP3, CDKN2A (p14ARF) and MLH1, some of which occur early on in the polyp→cancer sequence, which makes them especially promising as early detec tion markers. Methylated MLH1 is currently being used as a marker for sporadic as opposed to hereditary (that is, Lynch syndrome) MSI cancers ( Table 2 ). The vast majority of sporadic MSI tumors carry methyl ated MLH1, whereas it is infrequent in Lynch syndrome tumors. 166 Thus, methylated MLH1 status can be used to identify individuals who should be considered for genetic testing for Lynch syndrome. CIMP status has also been assessed as a predictive marker for 5fluorouracil (5FU) responsiveness; however, data surrounding the correlation between CIMP status and responsiveness to adjuvant 5FU therapy are conflicting. [167] [168] [169] Currently, no single hypermethylated gene has been identified that can predict the responsiveness of CRC to any one specific treatment with sufficient specificity and sensitivity to be used in a clinical theranostic assay.
Although efforts to find epigenetic markers for clinical use with CRC have mostly been focused on methylated genes-because of the inverse correla tion between CpG island methylation and global DNA hypomethylation 137, 138 -the role of LINE1 hypo methylation as a biomarker has also been investigated. LINE1 hypomethylation has shown promise as a prog nostic marker for reduced diseasefree survival in prox imal CRC. 170, 171 In addition, LINE1 methylation was lower in patients whose cancer recurred than in those whose cancer did not recur. 171 Ultimately, it is expected that a clinically useful assay will be developed in the near future that will incorporate a panel of methylated genes and mutant genes; however, to date, the data are not robust enough to support the use of any methylated genes as predictive biomarkers.
Conclusions
The role of epigenetics in the pathogenesis of cancer has come to the forefront over the past decade. It is now well established that epigenetic events can be driver events in the pathogenesis of CRC, and that these epigenetic events cooperate with gene mutations in the progression of normal colonic mucosa to colon cancer, with more genes in the colon cancer genome affected by altered DNA methylation than by gene mutations. Aberrant DNA methylation has been the most studied aspect of epi genetic alterations in CRC, and it is clear that global hypomethylation and local hypermethylation occur in the majority of CRCs. It has been shown that aber rant DNA methylation generally occurs early in the polyp→cancer sequence and that these changes contrib ute to the initiation of CRCs; however, some methyla tion changes occur later in the sequence and might also contribute to the progression of cancers.
These alterations in DNA methylation contribute to the molecular heterogeneity of CRCs, as illustrated by the identification of molecular subtypes of CRCs that can be identified by their unique methylated gene sig natures. Given the role of altered DNA methylation in directing the pathogenesis of CRC, studying DNA meth ylation signatures and developing them as bio markers for diagnosis, prognosis and direction of therapy is likely to yield clinically useful assays that will be used to direct patient care. However, the role of DNA methyla tion as a clinical biomarker is only just beginning to emerge. Finally, although the molecular mechanisms by which aberrant DNA methylation occurs are not yet fully understood, there are multiple models for cancer related aberrant methylation, involving mechanisms such as altered DNMT function and impaired barrier elements. These mechanisms probably cooperate to alter DNA methylation and other aspects of the epigenome in CRC. Continued efforts to investigate these mol ecular mechanisms will allow for a better understanding of the role of epigenetic alterations in CRC and will lead to the translation of these insights into the clinical arena.
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